<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006421.pub2" GROUP_ID="EYES" ID="627706010612275041" MERGED_FROM="" MODIFIED="2012-11-11 12:17:21 +0000" MODIFIED_BY="Anupa Shah" REVIEW_NO="VESU02" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.2">
<COVER_SHEET MODIFIED="2012-11-11 12:17:21 +0000" MODIFIED_BY="Anupa Shah">
<TITLE>Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery</TITLE>
<CONTACT MODIFIED="2012-11-11 12:17:21 +0000" MODIFIED_BY="Anupa Shah"><PERSON ID="11326" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Venki</FIRST_NAME><LAST_NAME>Sundaram</LAST_NAME><EMAIL_1>venkisundaram@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>c/o Cochrane Eyes and Vision Group, ICEH</DEPARTMENT><ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION><ADDRESS_1>Keppel Street</ADDRESS_1><CITY>London</CITY><ZIP>WC1E 7HT</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-11-11 12:17:21 +0000" MODIFIED_BY="Anupa Shah"><PERSON ID="11326" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Venki</FIRST_NAME><LAST_NAME>Sundaram</LAST_NAME><EMAIL_1>venkisundaram@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>c/o Cochrane Eyes and Vision Group, ICEH</DEPARTMENT><ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION><ADDRESS_1>Keppel Street</ADDRESS_1><CITY>London</CITY><ZIP>WC1E 7HT</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="9F7602EA82E26AA201609AF987C7F8B0" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Allon</FIRST_NAME><LAST_NAME>Barsam</LAST_NAME><SUFFIX>MA MRCOphth</SUFFIX><EMAIL_1>abarsam@hotmail.com</EMAIL_1><ADDRESS><ORGANISATION>Moorfields Eye Hospital NHS Foundation Trust</ORGANISATION><ADDRESS_1>City Road</ADDRESS_1><CITY>London</CITY><ZIP>EC1V 2PD</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="11340" ROLE="AUTHOR"><FIRST_NAME>Gianni</FIRST_NAME><LAST_NAME>Virgili</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Associate Professor of Ophthalmology</POSITION><EMAIL_1>gianni.virgili@unifi.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Specialised Surgical Sciences</DEPARTMENT><ORGANISATION>University of Florence</ORGANISATION><ADDRESS_1>Via le Morgagni 85</ADDRESS_1><CITY>Florence</CITY><ZIP>50134</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 055 411765</PHONE_1><FAX_1>+39 055 4377749</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-11-05 19:12:00 +0000" MODIFIED_BY="Iris Gordon">
<UP_TO_DATE>
<DATE DAY="15" MONTH="10" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="10" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="10" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="7" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2012-11-05 19:17:34 +0000" MODIFIED_BY="Anupa Shah">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-11-05 19:17:34 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="5" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>Issue 12 2012: No new trials were found that met the inclusion criteria.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-11-05 19:17:02 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="5" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>Issue 12 2012: The electronic searches were re-run for this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-03-30 14:50:24 +0100" MODIFIED_BY="Anupa Shah">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-30 14:50:24 +0100" MODIFIED_BY="Anupa Shah">
<DATE DAY="14" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-11-11 12:15:51 +0000" MODIFIED_BY="Anupa Shah">
<SUMMARY MODIFIED="2012-11-05 19:16:00 +0000" MODIFIED_BY="Gianni Virgili">
<TITLE MODIFIED="2012-11-05 19:16:00 +0000" MODIFIED_BY="Anupa Shah">Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy after retinal reattachment surgery</TITLE>
<SUMMARY_BODY MODIFIED="2010-05-11 21:37:13 +0100" MODIFIED_BY="Gianni Virgili">
<P>Proliferative vitreoretinopathy (PVR) is a retinal scarring process which occurs following retinal detachment. It is a major cause of failure of retinal reattachment surgery and impairment of ultimate visual recovery. Low weight molecular heparin (LMWH) and 5-Fluorouracil (5-FU) are agents that can be used during surgery to potentially reduce the amount of PVR following surgery. </P>
<P>The two studies included in this review looked at using LMWH with 5-FU during retinal detachment repair to see if there was an effect of reducing PVR levels after surgery. One study focused on patients who are considered at high-risk of developing PVR after surgery because of pre-existing ocular features, and found beneficial effects of this treatment in this group. The other study looked at a wider group of patients and did not find a benefit in using this combination treatment, and in certain patients the treatment was associated with poorer vision. Due to the inconsistency of the evidence, until further data are available, future research on the use of LMWH with 5-FU should be conducted only in retinal detachment patients who are likely to develop considerable retinal scarring after surgery.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-10-23 14:04:15 +0100" MODIFIED_BY="Anupa Shah">
<ABS_BACKGROUND MODIFIED="2009-06-15 21:09:26 +0100" MODIFIED_BY="[Empty name]">
<P>Proliferative vitreoretinopathy (PVR) is a significant cause of failure in retinal reattachment surgery. Various pharmacological agents have shown potential benefit in reducing postoperative PVR risk. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-08-19 11:27:29 +0100" MODIFIED_BY="Anupa Shah">
<P>This review aimed to compare the use of intravitreal low molecular weight heparin (LMWH) alone or with 5-Fluorouracil (5-FU) versus placebo, as an adjunct in the prevention of PVR following retinal reattachment surgery.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-10-23 14:04:15 +0100" MODIFIED_BY="Anupa Shah">
<P>We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (<I>The Cochrane Library</I> 2012, Issue 9), MEDLINE (January 1950 to October 2012), EMBASE (January 1980 to October 2012), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>) and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 15 October 2012.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-04-02 15:11:17 +0100" MODIFIED_BY="Anupa Shah">
<P>We only included randomised controlled trials (RCTs) that compared intravitreal LMWH alone or with 5-FU, versus placebo for the prevention of postoperative PVR in patients undergoing primary vitrectomy for rhegmatogenous retinal detachment repair.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-08-19 11:28:55 +0100" MODIFIED_BY="Anupa Shah">
<P>Two review authors independently assessed trial quality and extracted data. The review authors contacted study authors for additional information.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-05-12 14:16:31 +0100" MODIFIED_BY="Anupa Shah">
<P>We included two RCTs (with a total of 789 participants) comparing LMWH with 5-FU infusion and placebo. However, we did not perform a meta-analysis because of significant heterogeneity between these studies. One study found a significant beneficial effect of LMWH with 5-FU in reducing postoperative PVR compared to placebo (RR: 0.48, 95% confidence interval: 0.25 to 0.92), in 174 patients who were viewed at high-risk of developing postoperative PVR. The other study included 615 unselected cases of rhegmatogenous retinal detachment and could not show a difference between LMWH with 5-FU infusion and placebo in reducing PVR rates (RR:1.45, 95% confidence interval: 0.76 to 2.76).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-05-12 14:18:01 +0100" MODIFIED_BY="Anupa Shah">
<P>Results from this review indicate that there is inconsistent evidence from two studies on patients at different risk of PVR on the effect of LMWH and 5-FU used during vitrectomy to prevent PVR. Future research should be conducted on high risk patients only, until a benefit is confirmed at least in this patient subgroup.  </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-11-05 19:13:02 +0000" MODIFIED_BY="Anupa Shah">
<BACKGROUND MODIFIED="2010-05-12 18:01:02 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-08-19 13:43:05 +0100" MODIFIED_BY="Anupa Shah">
<P>Proliferative vitreoretinopathy (PVR) is defined as the growth and contraction of cellular membranes within the vitreous cavity and on both sides of the retinal surfaces. It is an anomalous scarring process in retinal detachments (<LINK REF="REF-Rachal-1979" TYPE="REFERENCE">Rachal 1979</LINK>; <LINK REF="REF-SSG-1992" TYPE="REFERENCE">SSG 1992</LINK>). The condition is the result of proliferation of glial and retinal pigment epithelial cells, both of which normally act as supporting cells for the retina. The retinal epithelial cells change their function to become fibroblast-like cells, normally involved in wound healing and scarring, with contractile properties. The resultant tissue fibrosis and contracture distorts the inner retina resulting in further redetachment. A retinal detachment can be defined as a separation of the neurosensory retina from the underlying retinal pigment epithelium.<BR/>Retinal reattachment is achieved with one operation in 70.7% of cases, and after one or more operations in 97.5% of cases (<LINK REF="REF-Heimann-2006" TYPE="REFERENCE">Heimann 2006</LINK>). Proliferative vitreoretinopathy is the most common cause of failed surgery for rhegmatogenous retinal detachment (<LINK REF="REF-Rachal-1979" TYPE="REFERENCE">Rachal 1979</LINK>; <LINK REF="REF-SSG-1992" TYPE="REFERENCE">SSG 1992</LINK>). Rhegmatogenous retinal detachment can be defined as a retinal detachment occurring due to a retinal break or tear that allows the liquid vitreous to pass through the break and detach the retina. This is the most common type of detachment.</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-05-12 15:02:45 +0100" MODIFIED_BY="Anupa Shah">
<P>A high success rate in primary retinal detachment surgery remains the basis for the prevention of PVR. In cases that develop PVR, and in others identified initially as high-risk, the use of adjunctive medical agents is potentially of value in increasing surgical success rates. There are a number of studies showing a potential benefit from a variety of pharmacological interventions, including retinoic acid (<LINK REF="REF-Araiz-1993" TYPE="REFERENCE">Araiz 1993</LINK>; <LINK REF="REF-Campochiaro-1991" TYPE="REFERENCE">Campochiaro 1991</LINK>; <LINK REF="REF-Fekrat-1995" TYPE="REFERENCE">Fekrat 1995</LINK>; <LINK REF="REF-Verstraeten-1992" TYPE="REFERENCE">Verstraeten 1992</LINK>), dexamethasone (<LINK REF="REF-Hui-1993" TYPE="REFERENCE">Hui 1993</LINK>; <LINK REF="REF-Tano-1980" TYPE="REFERENCE">Tano 1980</LINK>; <LINK REF="REF-Tano-1981" TYPE="REFERENCE">Tano 1981</LINK>), colchicines (<LINK REF="REF-Kirmani-1983" TYPE="REFERENCE">Kirmani 1983</LINK>; <LINK REF="REF-Lemor-1986" TYPE="REFERENCE">Lemor 1986</LINK>), paclitaxel (taxol) (<LINK REF="REF-Daniels-1990" TYPE="REFERENCE">Daniels 1990</LINK>; <LINK REF="REF-van-Bockxmeer-1985" TYPE="REFERENCE">van Bockxmeer 1985</LINK>), daunorubicin (<LINK REF="REF-Wiedemann-1987" TYPE="REFERENCE">Wiedemann 1987</LINK>; <LINK REF="REF-Wiedemann-1991" TYPE="REFERENCE">Wiedemann 1991</LINK>), and 5-Fluorouracil (5-FU) with heparin (<LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>; <LINK REF="REF-Kumar-2003" TYPE="REFERENCE">Kumar 2003</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2010-05-12 18:01:02 +0100" MODIFIED_BY="[Empty name]">
<P>Low molecular weight heparin (LMWH) has been shown to reduce postoperative fibrin after vitrectomy (<LINK REF="REF-Iverson-1991" TYPE="REFERENCE">Iverson 1991</LINK>). Heparin binds to fibronectin and to a wide range of growth factors, including acidic and basic fibroblast growth factors and platelet-derived growth factors (<LINK REF="REF-Blumenkranz-1992" TYPE="REFERENCE">Blumenkranz 1992</LINK>). 5-FU inhibits DNA synthesis, inhibits fibroblast proliferation and has been effective in reducing rates of PVR in animal models (<LINK REF="REF-Blumenkranz-1984" TYPE="REFERENCE">Blumenkranz 1984</LINK>). 5-FU and LMWH have actions at different stages of the PVR process, and using these agents in conjunction may produce a synergistic effect.</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-08-19 11:51:37 +0100" MODIFIED_BY="Anupa Shah">
<P>Neither intravitreal LMWH nor 5-FU are in routine clinical use in retinal detachment procedures, and a systematic review may help to ascertain whether routine clinical use of such interventions are beneficial.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-04-02 15:11:32 +0100" MODIFIED_BY="Anupa Shah">
<P>To compare intravitreal LMWH alone or with 5-FU to placebo as an adjunct in the prevention of PVR following retinal reattachment surgery.</P>
<P>The null hypothesis is that there is no difference between intravitreal LMWH or 5-FU versus placebo as an adjunct for the prevention of PVR following retinal reattachment surgery.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-11-05 19:13:02 +0000" MODIFIED_BY="Anupa Shah">
<SELECTION_CRITERIA MODIFIED="2010-05-12 16:04:11 +0100" MODIFIED_BY="Anupa Shah">
<CRIT_STUDIES MODIFIED="2009-03-30 15:24:25 +0100" MODIFIED_BY="Anupa Shah">
<P>We included randomised controlled trials (RCTs) only.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-05-12 16:04:03 +0100" MODIFIED_BY="Anupa Shah">
<P>We included people who were aged 16 years or older and were undergoing primary vitrectomy surgery for rhegmatogenous retinal detachments. We excluded participants who had posterior penetrating trauma, proliferative diabetic retinopathy, corneal opacity sufficient to impair surgical view, premenopausal status (potential teratogenic risk) or previous vitrectomy (<LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-08-19 12:03:03 +0100" MODIFIED_BY="Anupa Shah">
<P>We considered the following interventions:<BR/>1. Intravitreal LMWH (added to vitrectomy infusion fluid).<BR/>2. Adjuvant intravitreal LMWH and 5-FU (added to vitrectomy infusion fluid).<BR/>3. Placebo (control group) - normal vitrectomy infusion fluid (balanced salt solution).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-05-12 16:04:11 +0100" MODIFIED_BY="Anupa Shah">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-08-19 12:02:17 +0100" MODIFIED_BY="Anupa Shah">
<P>The development of postoperative PVR. This was determined at follow-up visits with complete retinal examination within six months postoperatively. The presence or absence of PVR and the reattachment status of the retina were recorded.</P>
<P>Definitions and grading of PVR may vary in the included trials. We recorded the variations in the definitions and noted whether the outcome was measured using a validated technique in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
<P>The gold standard for defining and grading PVR is the new adaptation of the Retinal Society Classification described by the Silicone Study Group (<LINK REF="REF-Lean-1989" TYPE="REFERENCE">Lean 1989</LINK>). The 1983 Retina Society classification was modified in 1989 by the Silicone Study Group, whose classification differentiates between posterior and anterior forms of PVR and recognises three patterns of proliferation: diffuse, focal and subretinal.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-05-12 16:04:11 +0100" MODIFIED_BY="Anupa Shah">
<P>Reoperation rate and change in visual acuity within six months postoperatively.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects (severe, minor)</HEADING>
<P>Intraoperative ocular haemorrhage, postoperative ocular haemorrhage and retinal redetachment rate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Economic data</HEADING>
<P>The cost of combined LMWH and 5-FU is $6.00 (<LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>).</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-10-23 16:26:06 +0100" MODIFIED_BY="Anupa Shah">
<ELECTRONIC_SEARCHES MODIFIED="2012-10-23 16:26:06 +0100" MODIFIED_BY="Anupa Shah">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2012, Issue 9, part of <I>The Cochrane Library</I>. <A HREF="http://www.thecochranelibrary.com/">www.thecochranelibrary.com</A> (accessed 15 October 2012), MEDLINE (January 1950 to October 2012), EMBASE (January 1980 to October 2012), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>) and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 15 October 2012.</P>
<P>See: Appendices for details of search strategies for CENTRAL (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), <I>m</I>RCT (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), ClinicalTrials.gov (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>) and and the ICTRP (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-03-30 15:37:37 +0100" MODIFIED_BY="Anupa Shah">
<P>The lead author searched the reference lists of the studies included in the review for information about further trials. We did not handsearch journals or conference proceedings specifically for the review.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-11-05 19:13:02 +0000" MODIFIED_BY="Anupa Shah">
<STUDY_SELECTION MODIFIED="2009-08-19 13:43:11 +0100" MODIFIED_BY="Anupa Shah">
<P>Two authors, working independently, assessed the titles and abstracts resulting from the searches. The full copy of all possibly or definitely relevant studies were obtained for further assessment. Both authors assessed these full copies to see if they did indeed meet the inclusion criteria. The lead author contacted study authors for clarification of any details necessary in order to make a complete assessment of the relevance of a study.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-10-23 16:42:25 +0100" MODIFIED_BY="Anupa Shah">
<P>We extracted data from each study, ensuring that the patients met the criteria described above under participants, and looked at the outcome measures described above. We looked at dichotomous data for the primary outcomes and at continuous data for the secondary outcomes listed above. The unit of analysis was an individual person.<BR/>Data were entered into Review Manager 5 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) by two authors working independently and checked in Review Manager 5. We approached the trial authors for information on missing data or where data were difficult to determine from the full copy of the paper.</P>
<P>We extracted the following study characteristics from each study included:</P>
<OL>
<LI>Methods: method of allocation, masking (participant, provider, outcome), exclusions after randomisation, losses to follow-up and compliance, unusual study design.</LI>
<LI>Participants: country where participants enrolled, number randomised, age, sex, main inclusion and exclusion criteria.</LI>
<LI>Interventions: treatment, comparison intervention (control), duration of intervention.</LI>
<LI>Outcomes: relevant outcomes on which data were collected in the trial and length of follow-up.</LI>
<LI>Notes: additional details relevant to that particular trial (e.g. funding sources).</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-11-05 19:13:02 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed all full copies for inclusion in the review for methodological quality according to Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 (</I>
<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>
<I>)</I>. We considered five parameters of quality:</P>
<OL>
<LI>Randomisation sequence generation</LI>
<LI>Allocation concealment</LI>
<LI>Masking of surgeon and patients</LI>
<LI>Incomplete outcome data</LI>
<LI>Selective reporting</LI>
</OL>
<P>We assessed each parameter of trial quality and graded it as low risk of bias, high risk of bias or unclear.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-10-23 16:55:12 +0100" MODIFIED_BY="[Empty name]">
<P>For dichotomous outcomes we calculated a summary relative risk. We calculated a mean difference for continuous outcomes. We will calculate a standardized mean difference if different scales are used to measure continuous outcomes in studies found when updating this review (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-05-11 21:27:15 +0100" MODIFIED_BY="Gianni Virgili">
<P>We did not expect such an issue to be found because these intervention are generally unilateral.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-06-16 10:26:48 +0100" MODIFIED_BY="Anupa Shah">
<P>When there were missing data in a study, unless causes of missingness could not be associated to treatment allocation such as death or patient refused surgery, we used Stata software 11.0 <I>metamiss </I>macro (<LINK REF="REF-White-2008" TYPE="REFERENCE">White 2008</LINK>) to explore the impact of missing data assuming fixed and opposite informative missing odds ratio (IMOR) 2 or 1/2.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-06-16 10:32:59 +0100" MODIFIED_BY="Anupa Shah">
<P>The inconsistency of effect estimates across studies was assessed using the I<SUP>2</SUP> statistic and the Chi<SUP>2</SUP> test for heterogeneity. If the I<SUP>2</SUP> statistic was greater than 50% we considered that to be substantial heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-05-11 21:27:16 +0100" MODIFIED_BY="Gianni Virgili">
<P>If a sufficient number of studies is found (10 or more) in the updates of this review, we will examine the symmetry of the funnel plot to explore small study and publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-10-23 16:55:12 +0100" MODIFIED_BY="[Empty name]">
<P>For future updates to this review, data analysis will be performed according to the guidelines in Chapter 9 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
<P>If the I<SUP>2</SUP> statistic is greater than 50% and if there is significant clinical heterogeneity we will not conduct a meta-analysis. Instead we will present a tabulated or narrative summary, or both. If the I<SUP>2</SUP> statistic is less than 50%, there is no significant clinical heterogeneity and there is no funnel plot asymmetry, we will combine the effect estimates in a meta-analysis using a random-effects model. We will use a fixed-effect model if there is no statistical or clinical heterogeneity and if the number of trials is fewer than three. This is to avoid reporting less robust effect estimates that may result from random-effects models in situations with very few trials.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-05-12 15:24:21 +0100" MODIFIED_BY="Anupa Shah">
<P>For future updates of this review, we will conduct subgroup analyses to investigate for heterogeneity if more studies are found and meta-analysis is possible. The subgroups will be based on: high versus low risk of PVR among controls (greater than 10%), attached versus detached macula, methods and timing used to deliver 5-FU.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-06-16 10:30:00 +0100" MODIFIED_BY="Anupa Shah">
<P>For future updates to this review, we will conduct sensitivity analyses to evaluate the impact of variations in definitions of outcomes used in different included trials. We will exclude studies graded as 'no' (high risk of bias) and 'unclear' in assessment of methodological quality. We will examine the impact of excluding studies of lower methodological quality, unpublished data, and industry-funded studies. We will examine whether the summary effect estimate is influenced by any assumptions that have been made during the review.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-10-23 16:27:15 +0100" MODIFIED_BY="Anupa Shah">
<STUDY_DESCRIPTION MODIFIED="2012-10-23 16:27:15 +0100" MODIFIED_BY="Anupa Shah">
<SEARCH_RESULTS MODIFIED="2012-10-23 16:27:15 +0100" MODIFIED_BY=" Iris Gordon">
<P>The electronic searches revealed 309 articles, of which, we identified two RCTs that met our inclusion criteria and were included in the review (<LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>; <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK>). We rejected two papers after obtaining the full text copies (<LINK REF="STD-Scheer-2005" TYPE="STUDY">Scheer 2005</LINK>, <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>). The other 305 articles were either not RCTs or did not specifically concern patients undergoing primary vitrectomy for retinal detachment, and were rejected by viewing their abstract alone.</P>
<P>An update search was done in October 2012 which yielded 65 records. The Trials Search Co-ordinator scanned the search results and removed 54 references which were not relevant to the scope of the review. We screened the title and abstracts of the remaining 11 references but found no studies that would be eligible for inclusion in the review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-05-12 15:40:41 +0100" MODIFIED_BY="Anupa Shah">
<P>Two trials (<LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>; <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK>) were included in the review and details are given below. See the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table for more details.</P>
<SUBSECTION>
<HEADING LEVEL="5">Types of participants</HEADING>
<P>
<LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK> recruited 174 patients undergoing primary vitrectomy for rhegmatogenous retinal detachments. All patients were more than 16 years of age and were deemed at high-risk of developing PVR. A regression formula derived from previous studies performed in the groups&#8217; department was used to identify patients at high-risk of developing PVR. Risk factors for developing PVR in descending importance were aphakia, preoperative PVR, size of detachment, anterior uveitis, previous cryotherapy and vitreous haemorrhage. Exclusion criteria were posterior penetrating trauma, proliferative diabetic retinopathy, corneal opacity sufficient to impair surgical view, premenopausal status, previous vitrectomy, inability to complete follow-up program and unwillingness to accept randomisation. Patients were followed up for six months following surgery.</P>
<P>
<LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK> recruited 641 patients from two specialised vitreoretinal units with rhegmatogenous retinal detachment, undergoing primary vitrectomy with gas tamponade. All patients were over 16 years of age, and unlike <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>, also included patients who were not viewed at being at risk of developing postoperative PVR. Additional exclusion criteria to <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK> included giant retinal tears (defined as peripheral retinal tears greater than three clock hours in circumferential extent), intended silicone oil tamponade and no light perception preoperative vision.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Types of interventions</HEADING>
<P>In <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK> and in <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK> patients in the treatment group received a continuous infusion of 5-FU (200 ug/ml) and LMWH (5 IU/ml). Normal saline was used as the infusion in the placebo group. In <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK>, silicone oil use was counted as a protocol violation and these patients were included for analysis. The number of protocol violations was similar between the two groups (N=15 in the treatment group and N=18 in the placebo group), so this is unlikely to have caused significant bias.</P>
<P>In <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>, if the operation lasted for more than one hour the infusion bag was replaced with a new identical infusion, whereas in <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK>, the infusion bag was replaced with Hartmann solution irrespective of the group.</P>
<P>All patients underwent standard three-port pars plana vitrectomy, with retinopexy using endolaser, indirect laser or cryotherapy where appropriate. Internal tamponade was achieved with either perfluoropropane (C3F8) gas<SUB> </SUB>or sulphur hexafluoride (SF6) gas.<SUB> </SUB>Silicone oil was used when indicated in <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Types of outcome measures</HEADING>
<P>In <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>, the primary outcome measure was postoperative PVR, defined as PVR greater than CP1 according to the new Retinal Society Classification. Secondary outcome measures were reoperation rate, change in visual acuity and complication rates. Treatment success was defined as complete retinal reattachment and no reoperations within six months.</P>
<P>In <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK>, the primary outcome measure was retinal reattachment after primary vitrectomy without reoperation at six months. Secondary outcome measures were occurrence and grade of PVR (grade C and above), best corrected visual acuity, intraocular pressure, corneal clarity and complications.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-06-16 10:31:51 +0100" MODIFIED_BY="Anupa Shah">
<P>We excluded two studies. One study (<LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>) appeared to meet our inclusion criteria from the abstract. The rest of the study was published in Chinese. We contacted Dr. Wang Yong directly who confirmed that the study was not an RCT and so was excluded from the review. The second study, <LINK REF="STD-Scheer-2005" TYPE="STUDY">Scheer 2005</LINK> was rejected after reviewing the full copy as it was not an RCT.</P>
<P>See the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table for further details.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-05-19 12:57:31 +0100" MODIFIED_BY="Anupa Shah">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<ALLOCATION MODIFIED="2009-08-19 13:24:37 +0100" MODIFIED_BY="Anupa Shah">
<P>In both studies, randomisation was carried out after patients had been scheduled for surgery and recruited and was performed with the help of a medical statistics support office. A randomisation schedule was used by the pharmacy department who then dispensed coded vials of treatment drugs or placebo.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-08-19 13:24:48 +0100" MODIFIED_BY="Anupa Shah">
<P>In both studies, the patients and surgeons were masked (blinded) to the type of infusion fluid being used.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-05-12 15:45:02 +0100" MODIFIED_BY="Anupa Shah">
<P>In both studies data were analysed according to the group to which patients were assigned (i.e. on an intention-to-treat basis).</P>
<P>In <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>, data for 5/87 patients in the placebo group and 2/87 patients in the treatment group were missing at three and six month follow up examinations. A simulation on these data as described in the '<LINK TAG="DATA_COLLECTION" TYPE="SECTION">Data collection and analysis</LINK>' section did not substantially change the results.</P>
<P>In <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK>, six month follow up data was incomplete for 15/342 patients in the treatment group and 11/299 patients in the placebo group. We suggest there is no need to carry out simulations on the impact of missing data since the loss was balanced and its causes were also similar and unlikely to be related to treatment outcome (surgery cancelled or patient did not attend or withdrew consent, death).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-05-11 21:27:16 +0100" MODIFIED_BY="Gianni Virgili">
<P>The primary outcome of this review was reported by both studies included in this review using the same definition. Re-operation rates were also reported. Visual acuity change was defined differently in the two studies: <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK> used a three-level categorisation (worse, stable, better), while <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK> reported continuous logMAR visual acuity as median and interquartile range. Thus, there is potential selective reporting, but only regarding this secondary outcome in our review.</P>
<P>We could not investigate publication bias due to the fact that only two studies are included in the review.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-05-18 15:47:08 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">5-Fluorouracil and LWMH versus placebo</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Primary outcome: postoperative PVR</I>
</HEADING>
<P>We did not perform a meta-analysis since <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK> and <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK> yielded estimates of effect in the opposite direction which were heterogeneous (Chi<SUP>2</SUP> test for heterogeneity P = 0.02 and I<SUP>2</SUP> 82% in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Only <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK> yielded a statistical significant difference favouring LMWH with 5-FU.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Secondary outcomes:</I>
</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>1. Reoperation rates</I>
</HEADING>
<P>High heterogeneity between <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK> and <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK> was also seen for reoperation rates (Chi<SUP>2</SUP> test for heterogeneity P = 0.08 and I<SUP>2</SUP> 67% in <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), but in this case neither study yielded a statistically significant difference between the two groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>2. Change in visual acuity</I>
</HEADING>
<P>The two included studies reported visual acuity differently.</P>
<P>We could extract the proportion of people in whom visual acuity had worsened at the last examination from <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>, and the comparison favoured LMWH with 5-FU (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>In <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK>, data were presented as median and interquartile range (IQR). Since there was little evidence of skewness (i.e. the median was roughly centred in the IQR), we used it to approximate means and we used IQR as an estimate of standard deviation (times 1.35 as suggested in <LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). After such data manipulation we could not show a difference between LMWH with 5-FU and placebo (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>3. Complications</I>
</HEADING>
<P>In <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK>, five patients developed postoperative hyphaema in each group, all of which were mild and settled with conservative treatment. One retinal incarceration and one choroidal haemorrhage occurred in the treatment group.</P>
<P>In <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK>, choroidal haemorrhage occurred in one patient in both the placebo and treatment groups. Two patients had retinal incarceration in the treatment group.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-06-16 10:38:32 +0100" MODIFIED_BY="Anupa Shah">
<SUMMARY_OF_RESULTS MODIFIED="2010-06-16 10:38:32 +0100" MODIFIED_BY="Anupa Shah">
<P>Although two trials were included in this review, we did not perform meta-analysis because of statistical heterogeneity between the trials for both the primary and the secondary anatomic outcome. This is further substantiated by clinical heterogeneity due to inclusion criteria leading to very different preoperative viewed risk of developing postoperative PVR. Such different inclusion criteria lead to different rates of PVR in the control group of each study (26% for <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK> and 5% for <LINK REF="STD-Wickham-2007" TYPE="STUDY">Wickham 2007</LINK>). The fact that only <LINK REF="STD-Asaria-2001" TYPE="STUDY">Asaria 2001</LINK> found LMWH with 5-FU beneficial to prevent postoperative PVR could be ascribed to an interaction of treatment with baseline risk, i.e. the control event rate. The rationale for this difference would be that LMWH with 5-FU infusion would only be effective in preventing postoperative PVR in patients undergoing primary vitrectomy for rhegmatogenous retinal detachment who were viewed at high-risk of developing postoperative PVR, whereas in cases of rhegmatogenous retinal detachment at low risk of PVR development its use might be associated with a worse visual outcome in macular sparing detachments as there are concerns about the use of a cytotoxic agent in a continuous infusion such as 5-FU.</P>
<P>However, the hypothesis of an interaction between baseline risk and treatment effect cannot be tested formally in subgroup analysis in our review with only two included studies, so this explanation remains presumptive.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-05-19 12:56:30 +0100" MODIFIED_BY="Anupa Shah">
<P>The heterogeneous results of the two studies regarding the direction of the effect for the primary outcome may suggest that heterogeneity is to be expected in studies on the use of LMWH and 5-FU to prevent PVR during vitrectomy. This is in agreement with the fact that this is a complex surgical procedure which can be applied to very different patients. Thus, the evidence collected in this review is largely incomplete and insufficient to guide clinical practice.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-05-11 21:27:16 +0100" MODIFIED_BY="Gianni Virgili">
<P>Overall, the studies were good quality, but the inconsistency of their results makes any conclusion difficult to be drawn. </P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-05-12 15:57:51 +0100" MODIFIED_BY="Anupa Shah">
<IMPLICATIONS_PRACTICE MODIFIED="2010-05-12 15:57:06 +0100" MODIFIED_BY="Anupa Shah">
<P>There is currently inconsistent evidence from randomised controlled trials on the efficacy of LMWH with 5-FU infusion to prevent PVR after vitrectomy for retinal detachment.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-05-12 15:57:51 +0100" MODIFIED_BY="Anupa Shah">
<P>Future research on LMHW and 5-FU during vitrectomy should be conducted on patients at high risk of PVR, both because there are ethical and theoretical reasons favouring this choice and to enhance study power. Studies on low risk patients should be a later step if treatment is found beneficial in studies on high risk patients.</P>
<P>Furthermore, a 2x2 block design may be used to investigate the separate effect of 5-FU or LMWH as well as their interaction. In addition, trials looking at the use of a LMWH combined with an intravitreal 5-FU injection at the end of a vitrectomy procedure, would be helpful in identifying routes and doses of administration of therapies that help prevent postoperative PVR in high-risk cases, and are also universally considered as safe approaches.  </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-11-11 12:15:51 +0000" MODIFIED_BY="Anupa Shah">
<P>The Cochrane Eyes and Vision Group created and executed the search strategies. We thank James Bainbridge, Catey Bunce and Ann Ervin for peer review comments. Anupa Shah, Managing Editor and Iris Gordon for providing CEVG resources. In addition, we thank Taixiang Wu for assistance with Chinese language articles.</P>
<P>Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-05-11 22:11:27 +0100" MODIFIED_BY="Gianni Virgili">
<P>Conceiving the review: AB<BR/>Designing the review:AB<BR/>Coordinating the review: VS<BR/>Data collection for the review<BR/>- Designing search strategies: Cochrane Eyes and Vision Group Trials Search Co-ordinator<BR/>- Undertaking searches: VS<BR/>- Screening search results: VS, AB<BR/>- Organising retrieval of papers: VS<BR/>- Screening retrieved papers against inclusion criteria: VS, AB<BR/>- Appraising quality of papers: VS, AB, GV<BR/>- Extracting data from papers: VS, AB, GV<BR/>- Writing to authors of papers for additional information: VS<BR/>- Providing additional data about papers: VS<BR/>- Obtaining and screening data on unpublished studies: VS<BR/>Data management for the review<BR/>- Entering data into RevMan (independently): VS, AB, GV<BR/>- Analysis of data: VS, AB, GV<BR/>Interpretation of data<BR/>- Providing a methodological perspective: VS, GV<BR/>- Providing a clinical perspective: VS<BR/>- Providing a policy perspective: VS<BR/>- Providing a consumer perspective: VS<BR/>- Writing the review: VS, AB, GV<BR/>- Providing general advice on the review: VS, AB<BR/>- Securing funding for the review: VS<BR/>- Performing previous work that was the foundation of the current study: AB<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-06-16 10:42:02 +0100" MODIFIED_BY="Anupa Shah">
<P>Minor changes have been made to the following sections:<BR/>1. Assessment of risk of bias in included studies: five quality parameters are now considered.<BR/>2. Dealing with missing data: simulation will be used to explore the impact of missing data.<BR/>3. Measures of treatment effect: the use of relative risk and mean difference is reported.<BR/>4. Data synthesis section has been reorganised.<BR/>5. Subgroup analysis and investigation of heterogeneity: introduced and subgroups defined for future updates of this review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-10-23 17:20:30 +0100" MODIFIED_BY="Anupa Shah">
<STUDIES MODIFIED="2010-05-18 15:17:07 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-08-24 15:29:48 +0100" MODIFIED_BY=" Iris Gordon">
<STUDY DATA_SOURCE="PUB" ID="STD-Asaria-2001" MODIFIED="2009-08-24 15:29:48 +0100" MODIFIED_BY=" Iris Gordon" NAME="Asaria 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-08-24 15:29:48 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, et al</AU>
<TI>Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : results from a randomized, double-blind, controlled clinical trial</TI>
<SO>Ophthalmology</SO>
<YR>2001</YR>
<VL>108</VL>
<NO>7</NO>
<PG>1179-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wickham-2007" MODIFIED="2009-08-24 15:18:52 +0100" MODIFIED_BY=" Iris Gordon" NAME="Wickham 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-24 15:18:52 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wickham L, Bunce C, Wong D, McGurn D, Charteris DG</AU>
<TI>Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy</TI>
<SO>Ophthalmology</SO>
<YR>2007</YR>
<VL>114</VL>
<NO>4</NO>
<PG>698-704</PG>
<IDENTIFIERS MODIFIED="2009-03-10 14:26:32 +0000" MODIFIED_BY="Venki Sundaram"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-05-18 15:17:07 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Scheer-2005" MODIFIED="2010-05-18 15:17:07 +0100" MODIFIED_BY="[Empty name]" NAME="Scheer 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-18 15:17:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheer S, Morel C, Poisson F, Bonnel S, Touzeau O, Sahel JA, et al</AU>
<TI>Prevention of proliferative vitreoretinopathy using 5-FU heparin: clinical tolerance and efficacy</TI>
<SO>Journal Francais d' Opthalmologie</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>7</NO>
<PG>701-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-03-10 14:56:18 +0000" MODIFIED_BY="Venki Sundaram"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2009-08-24 15:27:55 +0100" MODIFIED_BY=" Iris Gordon" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-24 15:27:55 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Wang LL, Zhu ZQ, Liu B, Pan AZ, Huang L</AU>
<TI>Electroretinogram of 5-fluorouracil and LMWH prevention of proliferative vitreoretinopathy</TI>
<SO>International Journal of Ophthalmology</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>3</NO>
<PG>651-3</PG>
<IDENTIFIERS MODIFIED="2009-08-24 15:22:37 +0100" MODIFIED_BY=" Iris Gordon"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-10-23 17:20:30 +0100" MODIFIED_BY="Anupa Shah">
<ADDITIONAL_REFERENCES MODIFIED="2012-10-23 17:19:33 +0100" MODIFIED_BY="Anupa Shah">
<REFERENCE ID="REF-Araiz-1993" MODIFIED="2012-10-23 16:47:25 +0100" MODIFIED_BY="[Empty name]" NAME="Araiz 1993" TYPE="JOURNAL_ARTICLE">
<AU>Araiz JJ, Refojo MF, Arroyo MH, Leong FL, Albert DM, Tolentino FI</AU>
<TI>Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>3</NO>
<PG>522-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blumenkranz-1984" MODIFIED="2010-05-19 13:38:40 +0100" MODIFIED_BY="Anupa Shah" NAME="Blumenkranz 1984" TYPE="JOURNAL_ARTICLE">
<AU>Blumenkranz M, Hernandez E, Ophir A, Norton EW</AU>
<TI>5-Fluorouracil: new applications in complicated retinal detachment for an established metabolite</TI>
<SO>Ophthalmology</SO>
<YR>1984</YR>
<VL>91</VL>
<NO>2</NO>
<PG>122-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blumenkranz-1992" MODIFIED="2009-08-24 15:55:06 +0100" MODIFIED_BY=" Iris Gordon" NAME="Blumenkranz 1992" TYPE="JOURNAL_ARTICLE">
<AU>Blumenkranz MS, Hartzer MK, Iverson D</AU>
<TI>An overview of potential applications of heparin in vitreoretinal surgery</TI>
<SO>Retina</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>Suppl 3</NO>
<PG>S71-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campochiaro-1991" MODIFIED="2012-10-23 16:53:00 +0100" MODIFIED_BY="[Empty name]" NAME="Campochiaro 1991" TYPE="JOURNAL_ARTICLE">
<AU>Campochiaro PA, Hackett SF, Conway BP</AU>
<TI>Retinoic acid promotes density-dependent growth arrest in human retinal pigment epithelial cells</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>1991</YR>
<VL>32</VL>
<NO>1</NO>
<PG>65-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Daniels-1990" MODIFIED="2012-10-23 16:54:32 +0100" MODIFIED_BY="[Empty name]" NAME="Daniels 1990" TYPE="JOURNAL_ARTICLE">
<AU>Daniels SA, Coonley KG, Yoshizumi MO</AU>
<TI>Taxol treatment of experimental proliferative vitreoretinopathy</TI>
<SO>Graefe's Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1990</YR>
<VL>228</VL>
<NO>6</NO>
<PG>513-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2012-10-23 16:55:59 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fekrat-1995" NAME="Fekrat 1995" TYPE="JOURNAL_ARTICLE">
<AU>Fekrat S, de Juan E Jr, Campochiaro PA</AU>
<TI>The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy</TI>
<SO>Ophthalmology</SO>
<YR>1995</YR>
<VL>102</VL>
<NO>3</NO>
<PG>412-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J</AU>
<TI>How to identify randomized controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heimann-2006" MODIFIED="2012-10-23 17:05:14 +0100" MODIFIED_BY="[Empty name]" NAME="Heimann 2006" TYPE="JOURNAL_ARTICLE">
<AU>Heimann H, Zou X, Jandeck C, Kellner U, Bechrakis NE, Kreusel KM, et al</AU>
<TI>Primary vitrectomy for rhegmatogenous retinal detachment: an analysis of 512 cases</TI>
<SO>Graefe's Archive for Clinical and Experimental Ophthalmology</SO>
<YR>2006</YR>
<VL>244</VL>
<NO>1</NO>
<PG>69-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-05-18 15:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hui-1993" MODIFIED="2012-10-23 17:05:45 +0100" MODIFIED_BY="[Empty name]" NAME="Hui 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hui YN, Liang HC, Cai YS, Kirchhof B, Heimann K</AU>
<TI>Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages</TI>
<SO>Graefe's Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1993</YR>
<VL>231</VL>
<NO>2</NO>
<PG>109-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iverson-1991" NAME="Iverson 1991" TYPE="JOURNAL_ARTICLE">
<AU>Iverson DA, Katsura H, Hartzer MK, Blumenkranz MS</AU>
<TI>Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1991</YR>
<VL>109</VL>
<NO>3</NO>
<PG>405-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirmani-1983" MODIFIED="2009-08-24 16:09:14 +0100" MODIFIED_BY=" Iris Gordon" NAME="Kirmani 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kirmani M, Santana M, Sorgente N, Wiedemann P, Ryan SJ</AU>
<TI>Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy</TI>
<SO>Retina</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>4</NO>
<PG>269-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2003" NAME="Kumar 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kumar A, Nainiwal S, Sreenivas B</AU>
<TI>Intravitreal low molecular weight heparin in PVR surgery</TI>
<SO>Indian Journal of Ophthalmology</SO>
<YR>2003</YR>
<VL>51</VL>
<NO>1</NO>
<PG>67-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lean-1989" NAME="Lean 1989" TYPE="JOURNAL_ARTICLE">
<AU>Lean JS, Stern WH, Irvine AR, Azen SP</AU>
<TI>Classification of proliferative vitreoretinopathy used in the silicone study. The Silicone Study Group</TI>
<SO>Ophthalmology</SO>
<YR>1989</YR>
<VL>96</VL>
<NO>6</NO>
<PG>765-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lemor-1986" NAME="Lemor 1986" TYPE="JOURNAL_ARTICLE">
<AU>Lemor M, Yeo JH, Glaser BM</AU>
<TI>Oral colchicine for the treatment of experimental traction retinal detachment</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1986</YR>
<VL>104</VL>
<NO>8</NO>
<PG>1226-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rachal-1979" NAME="Rachal 1979" TYPE="JOURNAL_ARTICLE">
<AU>Rachal WF, Burton TC</AU>
<TI>Changing concepts of failures after retinal detachment surgery</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1979</YR>
<VL>97</VL>
<NO>3</NO>
<PG>480-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-10-23 17:08:49 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Cochrane Collaboration</PB>
<CY>Copenhagen: The Nordic Cochrane Centre</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SSG-1992" MODIFIED="2012-10-23 17:18:02 +0100" MODIFIED_BY="[Empty name]" NAME="SSG 1992" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1992</YR>
<VL>110</VL>
<NO>6</NO>
<PG>770-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tano-1980" NAME="Tano 1980" TYPE="JOURNAL_ARTICLE">
<AU>Tano Y, Sugita G, Abrams G, Machemer R</AU>
<TI>Inhibition of intraocular proliferations with intravitreal corticosteroids</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1980</YR>
<VL>89</VL>
<NO>1</NO>
<PG>131-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tano-1981" NAME="Tano 1981" TYPE="JOURNAL_ARTICLE">
<AU>Tano Y, Chandler DB, McCuen BW, Machemer R</AU>
<TI>Glucocorticosteroid inhibition of intraocular proliferation after injury</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1981</YR>
<VL>91</VL>
<NO>2</NO>
<PG>184-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Bockxmeer-1985" MODIFIED="2012-10-23 17:18:39 +0100" MODIFIED_BY="[Empty name]" NAME="van Bockxmeer 1985" TYPE="JOURNAL_ARTICLE">
<AU>van Bockxmeer FM, Martin CE, Thompson DE, Constable IJ</AU>
<TI>Taxol for the treatment of proliferative vitreoretinopathy</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>1985</YR>
<VL>26</VL>
<NO>8</NO>
<PG>1140-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verstraeten-1992" MODIFIED="2012-10-23 17:19:04 +0100" MODIFIED_BY="[Empty name]" NAME="Verstraeten 1992" TYPE="JOURNAL_ARTICLE">
<AU>Verstraeten T, Hartzer M, Wilcox DK, Cheng M</AU>
<TI>Effects of vitamin A on retinal pigment epithelial cells in vitro</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>1992</YR>
<VL>33</VL>
<NO>10</NO>
<PG>2830-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2008" MODIFIED="2010-05-18 15:06:40 +0100" MODIFIED_BY="[Empty name]" NAME="White 2008" TYPE="JOURNAL_ARTICLE">
<AU>White IR, Higgins JP, Wood AM</AU>
<TI>Allowing for uncertainty due to missing data in meta-analysis--part 1: two-stage methods</TI>
<SO>Statistics in Medicine</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>5</NO>
<PG>711-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiedemann-1987" MODIFIED="2009-08-24 16:30:09 +0100" MODIFIED_BY=" Iris Gordon" NAME="Wiedemann 1987" TYPE="JOURNAL_ARTICLE">
<AU>Wiedemann P, Lemmen K, Schmiedl R, Heimann K</AU>
<TI>Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1987</YR>
<VL>104</VL>
<NO>1</NO>
<PG>10-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiedemann-1991" MODIFIED="2012-10-23 17:19:33 +0100" MODIFIED_BY="[Empty name]" NAME="Wiedemann 1991" TYPE="JOURNAL_ARTICLE">
<AU>Wiedemann P, Leinung C, Hilgers RD, Heimann K</AU>
<TI>Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy</TI>
<SO>Graefe's Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1991</YR>
<VL>229</VL>
<NO>2</NO>
<PG>150-2</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-10-23 17:20:30 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Sundaram-2010" MODIFIED="2012-10-23 17:20:30 +0100" MODIFIED_BY="[Empty name]" NAME="Sundaram 2010" TYPE="COCHRANE_REVIEW">
<AU>Sundaram V, Barsam A, Virgili G</AU>
<TI>Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2012-10-23 16:34:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-23 16:34:46 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006421.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-06-16 10:46:10 +0100" MODIFIED_BY="Anupa Shah">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-06-16 10:46:10 +0100" MODIFIED_BY="Anupa Shah" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-06-16 10:42:46 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Asaria-2001">
<CHAR_METHODS MODIFIED="2009-08-19 13:43:29 +0100" MODIFIED_BY="Anupa Shah">
<P>Double masked, prospective, randomised, placebo-controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-16 10:42:46 +0100" MODIFIED_BY="Anupa Shah">
<P>174 participants with rhegmatogenous retinal detachment who were also viewed at high-risk of developing postoperative PVR, undergoing primary vitrectomy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-02 15:11:46 +0100" MODIFIED_BY="Anupa Shah">
<P>Treatment group received a continuous intraocular LMWH and 5-FU infusion. Placebo group received normal saline infusion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-10 14:08:49 +0000" MODIFIED_BY="Venki Sundaram">
<P>Treatment group had significantly lower postoperative PVR rates.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-15 21:20:53 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-16 10:44:17 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Wickham-2007">
<CHAR_METHODS MODIFIED="2009-08-19 13:43:33 +0100" MODIFIED_BY="Anupa Shah">
<P>Double masked, prospective, randomised, placebo-controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-16 10:44:17 +0100" MODIFIED_BY="Anupa Shah">
<P>641 participants with rhegmatogenous retinal detachments from two specialist vitreoretinal units, with all participants undergoing primary vitrectomy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-19 13:43:34 +0100" MODIFIED_BY="Anupa Shah">
<P>Treatment group received a continuous intraocular LMWH and 5-FU infusion. Placebo group received normal saline infusion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-02 15:11:49 +0100" MODIFIED_BY="Anupa Shah">
<P>No significant difference in PVR rates between the two groups. Macular sparring detachments who received the LMWH and 5-FU infusion had a significantly worse visual acuity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>5-FU: 5-Fluorouracil<BR/>LMWH: low molecular weight heparin<BR/>PVR: proliferative vitreoretinopathy<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-05-14 10:58:53 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-04-02 15:10:30 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Scheer-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-02 15:10:30 +0100" MODIFIED_BY="Anupa Shah">
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-14 10:58:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-14 10:58:53 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-06-16 10:46:10 +0100" MODIFIED_BY="Anupa Shah">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-06-16 10:44:49 +0100" MODIFIED_BY="Anupa Shah" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 16:49:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asaria-2001">
<DESCRIPTION>
<P>Randomisation was carried out after the patient had been scheduled for surgery and recruited. Randomisation was performed with the help of the medical statistics support office, and a randomisation schedule was sent to the pharmacy department, which dispensed coded vials of treatment drugs or placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-16 10:44:49 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Wickham-2007">
<DESCRIPTION>
<P>After recruitment, non-trial personnel randomised participants on the day of surgery to the treatment or placebo groups using a computer generated weighted coin method.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-06-15 11:00:19 +0100" MODIFIED_BY="Anupa Shah" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 13:43:32 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Asaria-2001">
<DESCRIPTION>
<P>Coded vials of treatment or placebo were added to infusion bag just prior to surgery.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-15 11:00:19 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Wickham-2007">
<DESCRIPTION>
<P>Randomisation code kept on separate computer from investigators and pre-prepared coded infusion fluid used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-06-16 10:44:57 +0100" MODIFIED_BY="Anupa Shah" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Surgeons</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Participants</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-16 10:43:10 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Asaria-2001">
<DESCRIPTION>
<P>Participants masked (blinded) throughout study and treatment allocation only revealed at end of study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-08-19 13:41:49 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Asaria-2001">
<DESCRIPTION>
<P>Surgeons masked throughout study and treatment allocation only revealed at end of study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-16 10:44:57 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Wickham-2007">
<DESCRIPTION>
<P>Participants masked throughout and treatment allocation only revealed at end of study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-08-19 13:42:31 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Wickham-2007">
<DESCRIPTION>
<P>Surgeons masked throughout and treatment allocation only revealed at end of study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-06-16 10:46:10 +0100" MODIFIED_BY="Anupa Shah" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-06-16 10:43:54 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Asaria-2001">
<DESCRIPTION>
<P>Follow-up good and similar between both groups. 94.3% of participants in the placebo group and 97.7% of participants in the treatment group completed the six month follow-up visit.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-06-16 10:46:10 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Wickham-2007">
<DESCRIPTION>
<P>Follow-up good and similar between both groups. 96.3% of participants in the placebo group and 95.6% of participants in the treatment group completed the six month follow-up visit. Causes were also similar in the two groups and also unlikely to be related to treatment outcome (surgery cancelled, participant did not attend or withdrew consent, death).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-05-19 12:58:09 +0100" MODIFIED_BY="Anupa Shah" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-19 12:58:01 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Asaria-2001">
<DESCRIPTION>
<P>Selective reporting is not an issue for the primary outcome "development of PVR", or the secondary outcome "reoperation rate". It may be an outcome only for the secondary outcome "visual acuity" as this is a more subjective assessment and was defined differently in both included studies.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-19 12:58:09 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Wickham-2007">
<DESCRIPTION>
<P>Selective reporting is not an issue for the primary outcome "development of PVR", or the secondary outcome "reoperation rate". It may be an outcome only for the secondary outcome "visual acuity" as this is a more subjective assessment and was defined differently in both included studies.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-05-08 16:25:54 +0100" MODIFIED_BY="Gianni Virgili"/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-11-05 19:15:00 +0000" MODIFIED_BY="Anupa Shah">
<COMPARISON ID="CMP-001" MODIFIED="2012-11-05 19:15:00 +0000" MODIFIED_BY="Anupa Shah" NO="1">
<NAME>5-Fluorouracil (5-FU) plus low molecular weight heparin (LMWH) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-11-05 19:15:00 +0000" MODIFIED_BY="Gianni Virgili" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="414" TOTAL_2="375" WEIGHT="0.0" Z="0.0">
<NAME>Postoperative proliferative vitreoretinopathy (PVR)</NAME>
<GROUP_LABEL_1>5 FU + LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5 FU + LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9199534235689834" CI_START="0.24863591296818097" EFFECT_SIZE="0.4782608695652174" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="23" LOG_CI_END="-0.0362341600446933" LOG_CI_START="-0.6044361416740424" LOG_EFFECT_SIZE="-0.3203351508593678" MODIFIED="2010-03-28 18:29:41 +0100" MODIFIED_BY="Gianni Virgili" ORDER="7" O_E="0.0" SE="0.3337646566542505" STUDY_ID="STD-Asaria-2001" TOTAL_1="87" TOTAL_2="87" VAR="0.11139884603152969" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.758449779939912" CI_START="0.7589689155602923" EFFECT_SIZE="1.4469200524246395" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" LOG_CI_END="0.44066508164394397" LOG_CI_START="-0.11977601076734468" LOG_EFFECT_SIZE="0.16044453543829962" MODIFIED="2010-03-28 17:28:59 +0100" MODIFIED_BY="Gianni Virgili" ORDER="9" O_E="0.0" SE="0.32920587191054057" STUDY_ID="STD-Wickham-2007" TOTAL_1="327" TOTAL_2="288" VAR="0.10837650610037924" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="77" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-05-12 16:09:43 +0100" MODIFIED_BY="Anupa Shah" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="414" TOTAL_2="375" WEIGHT="0.0" Z="0.0">
<NAME>Reoperation rates (more than one procedure because of treatment failure)</NAME>
<GROUP_LABEL_1>5 FU + LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5FU/L</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2748099922487888" CI_START="0.45308712946397817" EFFECT_SIZE="0.76" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.1054454589133231" LOG_CI_START="-0.34381827435174045" LOG_EFFECT_SIZE="-0.11918640771920865" MODIFIED="2010-05-08 15:42:13 +0100" MODIFIED_BY="Gianni Virgili" ORDER="8" O_E="0.0" SE="0.26389974081124445" STUDY_ID="STD-Asaria-2001" TOTAL_1="87" TOTAL_2="87" VAR="0.06964307320024199" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9601097952347475" CI_START="0.9219298254636525" EFFECT_SIZE="1.344278126508933" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="38" LOG_CI_END="0.29228039897335073" LOG_CI_START="-0.035302134883206944" LOG_EFFECT_SIZE="0.12848913204507192" MODIFIED="2010-05-08 15:42:30 +0100" MODIFIED_BY="Gianni Virgili" ORDER="10" O_E="0.0" SE="0.19242360194703675" STUDY_ID="STD-Wickham-2007" TOTAL_1="327" TOTAL_2="288" VAR="0.03702684258627165" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-05-12 16:07:28 +0100" MODIFIED_BY="Anupa Shah" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="87" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Worsened final visual acuity</NAME>
<GROUP_LABEL_1>5 FU + LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5FU/LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9482397036850332" CI_START="0.3938421779557799" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="36" LOG_CI_END="-0.023081864319399327" LOG_CI_START="-0.4046777755707627" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2010-03-28 18:54:03 +0100" MODIFIED_BY="Gianni Virgili" ORDER="11" O_E="0.0" SE="0.2241513271992758" STUDY_ID="STD-Asaria-2001" TOTAL_1="87" TOTAL_2="87" VAR="0.050243817485196796" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2010-05-12 16:07:46 +0100" MODIFIED_BY="Anupa Shah" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="327" TOTAL_2="288" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Visual acuity at 6 months</NAME>
<GROUP_LABEL_1>5 FU + LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5FU/L</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.05153712678446478" CI_START="-0.05153712678446478" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.4" MODIFIED="2010-03-28 19:01:38 +0100" MODIFIED_BY="Gianni Virgili" ORDER="12" SD_1="0.35555" SD_2="0.296296" SE="0.02629493561666595" STUDY_ID="STD-Wickham-2007" TOTAL_1="327" TOTAL_2="288" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-06-16 10:46:11 +0100" MODIFIED_BY="Anupa Shah">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-06-16 10:46:11 +0100" MODIFIED_BY="Anupa Shah" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-10-23 16:31:33 +0100" MODIFIED_BY=" Iris Gordon">
<APPENDIX ID="APP-01" MODIFIED="2012-10-23 16:31:33 +0100" MODIFIED_BY=" Iris Gordon" NO="1">
<TITLE MODIFIED="2008-07-14 11:38:12 +0100" MODIFIED_BY="Anupa Shah">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-23 16:31:33 +0100" MODIFIED_BY=" Iris Gordon">
<P>#1 MeSH descriptor: [Vitreoretinopathy, Proliferative] explode all trees<BR/>#2 proliferative near/2 vitreoretinopath*<BR/>#3 MeSH descriptor: [Retinal Detachment] explode all trees<BR/>#4 MeSH descriptor: [Retinal Perforations] explode all trees<BR/>#5 MeSH descriptor: [Vitreous Detachment] explode all trees<BR/>#6 retina* near/2 break*<BR/>#7 retina* near/2 tear*<BR/>#8 retina* near/2 detach*<BR/>#9 retina* near/2 perforat*<BR/>#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9<BR/>#11 MeSH descriptor: [Heparin, Low-Molecular-Weight] explode all trees<BR/>#12 low molecular weight heparin<BR/>#13 lmwh<BR/>#14 MeSH descriptor: [Fibrinolytic Agents] explode all trees<BR/>#15 fibrinoly*<BR/>#16 coagulat*<BR/>#17 MeSH descriptor: [Fluorouracil] explode all trees<BR/>#18 fluorouracil<BR/>#19 flourouracil<BR/>#20 fluoro uracil<BR/>#21 5FU<BR/>#22 5 FU<BR/>#23 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22<BR/>#24 #10 and #23</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-10-23 16:24:13 +0100" MODIFIED_BY=" Iris Gordon" NO="2">
<TITLE MODIFIED="2012-10-23 16:19:30 +0100" MODIFIED_BY="Anupa Shah">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-23 16:24:13 +0100" MODIFIED_BY=" Iris Gordon">
<P>1. randomized controlled trial.pt.<BR/>2. (randomized or randomised).ab,ti.<BR/>3. placebo.ab,ti.<BR/>4. dt.fs.<BR/>5. randomly.ab,ti.<BR/>6. trial.ab,ti.<BR/>7. groups.ab,ti.<BR/>8. or/1-7<BR/>9. exp animals/<BR/>10. exp humans/<BR/>11. 9 not (9 and 10)<BR/>12. 8 not 11<BR/>13. Vitreoretinopathy, Proliferative/<BR/>14. (proliferative adj2 vitreoretinopath$).tw.<BR/>15. exp retinal detachment/<BR/>16. exp retinal perforation/<BR/>17. exp vitreous detachment/<BR/>18. (retina$ adj2 break$).tw.<BR/>19. (retina$ adj2 tear$).tw.<BR/>20. (retina$ adj2 detach$).tw.<BR/>21. (retina$ adj2 perforat$).tw.<BR/>22. or/13-21<BR/>23. exp heparin, low molecular weight/<BR/>24. (low adj2 molecular adj2 weight adj2 heparin).tw.<BR/>25. lmwh.tw.<BR/>26. exp fibrinolytic agents/<BR/>27. fibrinoly$.tw.<BR/>28. coagulat$.tw.<BR/>29. exp fluorouracil/<BR/>30. fluorouracil.tw.<BR/>31. flourouracil.tw.<BR/>32. fluoro uracil.tw.<BR/>33. 5FU$.tw.<BR/>34. 5 FU$.tw.<BR/>35. or/23-34<BR/>36. 22 and 35<BR/>37. 12 and 36</P>
<P>The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (<LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-10-23 16:25:29 +0100" MODIFIED_BY="Anupa Shah" NO="3">
<TITLE MODIFIED="2012-10-23 16:19:53 +0100" MODIFIED_BY="Anupa Shah">EMBASE (ovidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-23 16:25:29 +0100" MODIFIED_BY="Anupa Shah">
<P>1. exp randomized controlled trial/<BR/>2. exp randomization/<BR/>3. exp double blind procedure/<BR/>4. exp single blind procedure/<BR/>5. random$.tw.<BR/>6. or/1-5<BR/>7. (animal or animal experiment).sh.<BR/>8. human.sh.<BR/>9. 7 and 8<BR/>10. 7 not 9<BR/>11. 6 not 10<BR/>12. exp clinical trial/<BR/>13. (clin$ adj3 trial$).tw.<BR/>14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.<BR/>15. exp placebo/<BR/>16. placebo$.tw.<BR/>17. random$.tw.<BR/>18. exp experimental design/<BR/>19. exp crossover procedure/<BR/>20. exp control group/<BR/>21. exp latin square design/<BR/>22. or/12-21<BR/>23. 22 not 10<BR/>24. 23 not 11<BR/>25. exp comparative study/<BR/>26. exp evaluation/<BR/>27. exp prospective study/<BR/>28. (control$ or propspectiv$ or volunteer$).tw.<BR/>29. or/25-28<BR/>30. 29 not 10<BR/>31. 30 not (11 or 23)<BR/>32. 11 or 24 or 31<BR/>33. exp vitreoretinopathy/<BR/>34. (proliferat$ adj2 vitreoretinopath$).tw.<BR/>35. exp retinal tear/<BR/>36. exp retinal detachment/<BR/>37. exp vitreous body detachment/<BR/>38. (retina$ adj2 break$).tw.<BR/>39. (retina$ adj2 tear$).tw.<BR/>40. (retina$ adj2 detach$).tw.<BR/>41. (retina$ adj2 perforat$).tw.<BR/>42. or/33-41<BR/>43. exp heparin, low molecular weight/<BR/>44. (low adj2 molecular adj2 weight adj2 heparin).tw.<BR/>45. lmwh.tw.<BR/>46. exp fibrinolytic agents/<BR/>47. fibrinoly$.tw.<BR/>48. coagulat$.tw.<BR/>49. exp fluorouracil/<BR/>50. fluorouracil.tw.<BR/>51. flourouracil.tw.<BR/>52. fluoro uracil.tw.<BR/>53. 5FU$.tw.<BR/>54. 5 FU$.tw.<BR/>55. or/43-54<BR/>56. 42 and 55<BR/>57. 32 and 56<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-06-14 14:23:09 +0100" MODIFIED_BY=" Iris Gordon" NO="4">
<TITLE MODIFIED="2010-06-14 14:21:04 +0100" MODIFIED_BY=" Iris Gordon">
<I>meta</I>Register of Controlled Trials search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-06-14 14:23:09 +0100" MODIFIED_BY=" Iris Gordon">
<P>low molecular weight heparin AND retina</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2010-06-14 14:22:13 +0100" MODIFIED_BY=" Iris Gordon" NO="5">
<TITLE MODIFIED="2010-06-14 14:21:22 +0100" MODIFIED_BY=" Iris Gordon">ClinicalTrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-06-14 14:22:13 +0100" MODIFIED_BY=" Iris Gordon">
<P>low molecular weight heparin AND retina</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2012-10-23 16:19:00 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2012-10-23 14:08:03 +0100" MODIFIED_BY="[Empty name]">ICTRP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-23 16:19:00 +0100" MODIFIED_BY="[Empty name]">
<P>retina = Condition AND low molecular weight heparin = Intervention</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>